Introduction
KLF6 is a novel member of the Kruppel-like family initially isolated as an upregulated gene in activated stellate cells of the liver (Ratziu et al., 1998) . Kruppellike transcription factors (KLFs) contain a shared DNA-binding domain containing three C2H2 zincfingers (Turner and Crossley, 1999) . A growing list of KLF target genes has been identified. For example, GKLF (KLF4) activates p21(WAF1/Cip1) through a specific Sp1-like cis-element in the p21(WAF1/Cip1) proximal promoter and can form a complex with the tumor suppressor p53 (Zhang et al., 2000) . KLF6 transactivates the promoters of collagen a1(I) (Ratziu et al., 1998) , urokinase type plasminogen activator (Kojima et al., 2000) , TGF-b1, TGF-b1 receptors, and endoglin (Botella et al., 2002) .
KLF6 also plays a role in human cancer, since this gene is mutated in a significant fraction of human prostate carcinomas (Narla et al., 2001) . Moreover, prostate cancer-derived mutations leading to disruption of KLF6 function enhance the growth of cultured cells, supporting its role as a bona fide tumor suppressor (Narla et al., 2001 ). This growth suppressing activity has been attributed in part to promoter transactivation of the cyclin-dependent kinase inhibitor, p21. Interestingly, this transcriptional activity of KLF6 is p53-independent (Narla et al., 2001) . As expected, tumor-associated mutations in KLF6 abolish its ability to transactivate the p21 promoter. Thus, KLF6 represents member of a novel tumor-suppressor pathway whose inactivation in certain tumors may occur independent of the loss of p53.
The high incidence of KLF6 inactivation in prostate cancer is consistent with its localization to chromosome 10p15, a region frequently deleted in this malignancy (Narla et al., 2001) . Similarly, high frequency of loss of 10p15 has also been reported in glioblastoma multiforme (GBM) (Kimmelman et al., 1996; Voesten et al., 1997; Kon et al., 1998; Harada et al., 2000) . Malignant neoplasms of the brain, the majority of which are of glial origin, cause an average of more than 13 000 deaths annually. GBM is the most aggressive and prevalent of these glial tumors (Holland, 2000) . The prognosis of patients with GBM is extremely poor despite multimodality treatment, including surgical resection, radiation therapy, and chemotherapy. The median survival is approximately less than 1 year, and with only a 2% 5-year survival (Kleihues and Cavenee, 2000) .
We and others have previously demonstrated that the short arm of chromosome 10 (10p14-15) may harbor one or more tumor-suppressor loci involved in glioma progression (Kimmelman et al., 1996) . KLF6 is mapped to this region between two microsatellite repeat markers, D10S533 and D10S591. Genomic loss between these two markers has been reported in 10-50% of glial tumors of low and high grade (Kimmelman et al., 1996) . The hypothesis that KLF6 can be a glial tumor suppressor was further strengthened by the recent finding of tumor-associated KLF6 mutations in primary glioblastomas (Jeng and Hsu, 2003) . However, evidence that KLF6 does indeed possess the biological attributes of a tumor suppressor is still lacking. Here, we provide the first demonstration that KLF6 suppresses several biological properties of glioblastomas both in vitro and in vivo.
Results

Expression of KLF6 in human glioblastomas
In order to investigate the possible role of KLF6 in glial tumor progression, the expression level of this transcription factor was analyzed in a panel of glial tumor cell lines. The normal counterparts of these tumors were obtained from primary astrocytes derived from both human and mouse brains. An additional control was provided by a neural-derived cell line, DI TNC1. It is a rat astrocyte cell line established from a newborn rat brain and retains the characteristics of type I astrocytes (Radany et al., 1992) . As shown in Figure 1a , both primary astrocytes, and DI TNC1 expressed readily detectable levels of KLF6, which migrates as doublets of variable intensity within a size range of 35-43 kDa. The level of KLF6 expression was higher in DITNC1 than the two primary astrocyte cultures. To ascertain the molecular weight of human KLF6, a human KLF6 cDNA was ectopically overexpressed in PC3 prostate cancer cell line. Under this condition, human KLF6 was expressed as a doublet of 37 and 40 kDa in size. This doublet and its variable mobility among different cells are likely due to various phosphorylation states of KLF6 (S Friedman, unpublished data) .
When a panel of human glial tumor cell lines was examined by Western blot analysis, KLF6 expression was reduced in eight of nine samples when compared to primary human astrocytes (Figure 1a) . Apart from the cell line A2782, KLF6 levels were attenuated from 1.5-to 8.0-fold in the remaining tumor lines. Next, to examine if this low level of KLF6 expression in established cultures was also manifested in primary tumors, Western blot analysis was performed with total cell lysates derived from 13 randomly selected GBM surgical specimens. Using actin as a loading control, four out of 13 samples (1136, 1152, 1192, 1035 ) (B31%) displayed greater than 85% reduction in KLF6 expression when compared to primary human astrocytes. Moderate levels were, however, detected in six tumor specimens (1046, 1052, 1133, 1176, 1181, 1209) while three samples (1066, 1089, 1123) possessed higher levels of KLF6 expression. Interestingly, these tumor samples displayed a varying pattern of KLF6 isoforms, with several samples possessing only the lower molecular weight species (for example, 1046, 1123) . This data implies that full-length KLF6 expression may be lost or attenuated in a significant fraction of both primary tumors and established GBM cell lines.
KLF6 suppresses glioblastoma tumorigenicity and growth properties in vitro To further study the importance of KLF6 in the biology of glial tumors, KLF6 was introduced through retroviral-mediated gene transfer in the DBTRG-05MG glioblastoma cell line. As shown in Figure 2a , this cell line has very low endogenous expression of KLF6, and previous studies have shown that this line is monosomic for chromosome 10 with wild-type p53 alleles (Kruse et al., 1992) . Western blot analysis of marker-selected mass cultures revealed that KLF6 was expressed at a level below those of DI TNC1 astrocytes (Figure 2a) . The low level of ectopically expressed KLF6 in the stable lines thus provides a near-physiological system to study the effects of KLF6. Additionally, a mutant form of KLF6, KLF6-DN, which has the majority of the transactivation domain deleted was used as a negative control. This protein was undetectable, which we believe reflects the loss of major immunogenic epitopes recognized by the polyclonal antibody raised against the amino terminus of the protein. To confirm that the truncated protein could be expressed in this tumor, we transiently transfected expression constructs of FLAGtagged full-length KLF6 and KLF6-DN in DBTRG-05MG. Indeed, protein species of B40 and B17 kDa corresponding to the full-length and N-terminal truncated KLF6 were detected with an anti-FLAG antibody ( Figure 2a , right panel).
Most astrocytic cells express glial fibrillary acidic protein (GFAP), a marker of differentiated glial cells. DBTRG-05MG, on the other hand, represents a highly dedifferentiated tumor cell line and unlike the DI TNCI astrocytes, do not express GFAP (Figure 2a , left panel). Expression of KLF6 did not, however, upregulate GFAP in these tumor cells. It is, therefore, unlikely that KLF6 can alter the differentiation state of DBTRG-05MG. In addition, we observed a B3.0-fold increase in the level of p21/CIP1/WAF1 in the KLF6 transfectant ( Figure 2a ). This is consistent with the previous finding that KLF6 activates the transcription of this cell cycle inhibitor.
To examine if KLF6 could modify the transformed phenotype of DBTRG-05MG cells, we assayed the ability of these transfectants to grow in an anchorageindependent manner. As shown in Figure 2b , whereas vector-and KLF6-DN-transduced cells were able to form large colonies, the growth of KLF6-expressing cells in semisolid agar was markedly impaired by approximately 5.0-7.0 fold. In addition, these cells also displayed a slower proliferative rate than their control counterparts ( Figure 2c ). KLF6 expressing DBTRG-05MG showed a 43% reduction in cell numbers over a 5-day period when cultured in 5% serum (Figure 2c , inset). Next, we examined if both the reduction of colony formation in soft-agar growth as well as the slower cell growth correlated with the ability of KLF6 to transactivate the p21 promoter. When transiently cotransfected in DBTRG-05MG cells with a luciferase reporter plasmid containing the p21 promoter, KLF6 increased luciferase activity by B2.5-fold when compared to vector-transfected cells (Figure 2d ). Interestingly, the KLF6-DN construct appeared to slightly diminish basal transactivation of the promoter, which could explain its ability to moderately increase the proliferative rate in vitro.
To demonstrate that the growth-suppressive effects of KLF6 were not limited to a single cell line, an additional GBM line was infected with the same KLF6 retroviruses under similar experimental conditions. For this, we used the malignant glioma cell line, U87MG, which has a moderate level of KLF6 expression and similar to DBTRG-05MG, possesses wild-type p53 gene. U87MG cells transduced with KLF6 virus were able to express the B40 kDa KLF6 protein in a stable manner (Figure 3a) . Expression of the truncated KLF6-DN mutant was also monitored by transient transfection as described for DBTRG-05MG previously (Figure 3a , right panel). In addition, we did not observe any significant increases in levels of either GFAP (data not shown) or p21/CIP1/WAF1 in the KLF6 transfectant (Figure 3a, left panel) . Next, their in vitro growth rates were assessed, which were significantly attenuated by KLF6 by B36% (Figure 3b, inset) . Furthermore, a significant fraction of the KLF6-expressing U87MG cells reverted from a highly refractile to an overtly flattened cell morphology (dark arrows, Figure 3c ). In addition, some cells displayed striking cellular protrusions reminiscent of neurite outgrowth (white arrowheads, Figure 3c ). Thus, we conclude that KLF6 is capable of suppressing the in vitro growth properties of glioblastoma cell lines.
KLF6 inhibits cellular transformation induced by oncogenes
Several human oncogene products have been implicated in glial tumor progression. These include the increased Results are expressed as a fold over control-transfected cells, with all values normalized to total protein levels from an assay performed in triplicate. Similar results were obtained in an additional experiment expression/activation of receptors for epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) (Maher et al., 2001) . In addition, conditional expression of a RAS oncogene in glial cell lineages led to the formation of glioblastomas in an animal model (Ding et al., 2001) . Finally, animals harboring a v-src transgene underwent an early induction of angiogenesis in gliomas (Theurillat et al., 1999) . To analyse whether KLF6 was capable of blocking these oncogenic signals, focus-forming assays were performed in NIH 3T3 cells. To induce transformed foci, NIH 3T3 cells were transfected with plasmids expressing c-sis/PDGF-B, vsrc, H-Ras R12, or EGFR. Cells were either cotransfected with a control vector, a KLF6 expression plasmid, or the KLF6-DN mutant. As shown in Figure 4 , KLF6 expression was able to significantly block morphological transformation by PDGF-B, v-src, H-Ras R12 by B60%. KLF6 was, however, relatively less effective in inhibiting the transforming effect of EGFR. As expected, the ability of KLF6-DN mutant to produce similar inhibitory effect was markedly diminished.
KLF6 attenuates glioblastoma tumorigenicity in vivo
Based on its inhibitory activity in vitro, we assessed whether the expression of KLF6 in DBTRG-05MG affected tumorigenicity in vivo. Cells harboring either control or KLF6 expression plasmid were injected subcutaneously into nude mice and tumors were allowed to form. Tumor volume was measured on a weekly basis for 7 weeks prior to sacrificing. As depicted in Figure 5a , the majority of animals injected with tumor cells expressing KLF6 had decreased tumor volumes when compared to animals inoculated with cells expressing the vector control. Additionally, when grouped according to tumor volume, 60% of mice injected with control cells fell within the intermediate (3000-6000 mm 3 ) to largest (46000 mm 3 ) volumes, while only 10% of animals injected with KLF6-transduced cells induced tumors in these volume ranges (Figure 5a, right panel) . In fact, 90% of the mice injected with KLF6-expressing cells produced tumors with volumes smaller than 3000 mm 3 . These data were reproduced by using stable lines from an independent infection experiment ( Figure 5b ). In this case, while 4/7 of the animals injected with control cells harbored tumors of 410 000 mm 3 in size, only 1/7 of mice inoculated with KLF6-expressing cells managed to achieve this tumor volume. Thus, the expression of KLF6 in DBTRG-05MG glioblastoma cells leads to the attenuation of tumorigenic phenotypes both in vitro and in vivo.
Discussion
This report provides the first biological evidence that KLF6 possesses tumor-suppressing activity in vivo. We have shown that KLF6 expression is attenuated in a variety of glial tumor cell lines when compared with primary astrocytes. Expression of KLF6 in two GBM lines inhibits their transformed phenotypes in vitro and reduces their ability to form tumors in mice. Additionally, KLF6 may block proliferative signals associated with specific lesions found in glial tumors such as PDGFR or EGFR amplification, and the constitutive activation of the Ras-dependent signaling pathways. Our work complements the recent finding that KLF6 is mutated in 11.8% (9/76) of primary GBM samples (Jeng and Hsu, 2003) . The fact that 85% of tumors with KLF6 mutations have lost the remaining wild-type allele strongly suggests that KLF6 is a classical tumorsuppressor gene.
GBM can occur as a primary (de novo) tumor or derived from the progression of anaplastic astrocytoma (Maher et al., 2001) . The loss of 10p is frequently associated with primary GBM, which are characterized by EGFR overexpression and the lack of p53 mutations (Maher et al., 2001) . Since KLF6 can upregulate p21 independent of p53, this suggests that the loss of KLF6 and p53 in GBM may be mutually exclusive.
Additionally, the tumor suppressor PTEN, which is located on the long arm of chromosome 10, is mutated in a significant fraction of GBM (Kato et al., 2000) . Therefore, it will be interesting to analyse KLF6-deficient mice alone or in combination with other genetic backgrounds, such as PTEN (À/ þ ) or p53 (À/ þ ), for the development of glial tumors. Of note, PTEN heterozygous mice, while susceptible to tumors such as lymphomas, do not develop glial tumors, although the gene is found to be mutated in approximately 12% of gliomas (Podsypanina et al., 1999) . It is also interesting to note that chromosome 10 is monosomic in 460% and partially lost in up to 90% of higher-grade gliomas (Maher et al., 2001 ). In addition, using flanking microsatellite markers localized within 1 cM of the KLF6 gene, the frequency was observed to be as high as 70% (J Martignetti and B Feuerstein, unpublished observations). Therefore, it is very likely that the inactivation of KLF6, PTEN as well as several other tumor-suppressor genes on this chromosome contribute to tumor progression. The availability of a knockout mouse model for KLF6 will allow these possibilities to be tested.
Functional loss of KLF6 may occur on several levels, as we failed to detect genetic alterations of this transcription factor in the limited number of cell lines examined (data not shown). We speculate that the reduced expression of KLF6 may occur either by the loss of an entire or portion of chromosome 10 at loci flanking KLF6, while subsequent alterations leading to the abolition of KLF6 expression could reflect epigenetic mechanisms. For example, the reduced transcription from Apaf-1 due to promoter methylation has been observed in some melanomas (Soengas et al., 2001) . Alternatively, overexpression of Mdm2, which is an E3 ubiquitin ligase, promotes the degradation of the p53 tumor suppressor through a proteosome-dependent pathway (Honda et al., 1997) . Finally, it is also possible that the loss of the single allele of KLF6 may lead to tumor progression through a haploinsufficency mechanism. However, a more extensive analysis of primary glial tumors and additional GBM cell lines is necessary to ascertain the frequency of KLF6 loss and/or inactivation in GBM.
The ability of KLF6 to suppress the transforming activity of several oncogenes in NIH 3T3 cells is potentially important. This observation is unlikely due to a general toxic effect of KLF6 on NIH3T3 cells since it does not significantly reduce the number of markerselectable colony in conventional colony-forming assays (data not shown). Most receptor tyrosine kinase oncogenes such as PDGFR and EGFR are dependent on Ras and Src for their signaling events (Satoh et al., 1990; Broome and Hunter, 1996) . Interestingly, p21/ CIP1/WAF1, a KLF6 target gene, blocks cellular transformation by a variety of oncogenes, which could provide a mechanism through which KLF6 inhibits tumor cell growth (Givol et al., 1995) . Whether KLF6 could directly block components of signaling pathways emanated from these oncogenes in GBM is by far unknown.
Attenuation of GBM growth by KLF6 could potentially be an avenue for therapeutic intervention. Indeed, since only a modest level of KLF6 is necessary to suppress tumor growth, this gene is an attractive candidate for gene therapy approaches. More importantly, the frequent genomic loss in this region in multiple tumor types implies that KLF6 may represent an important tumor suppressor for a broad range of human cancers.
Materials and methods
Cell culture, generation of stable lines, and tumor specimens GBM cell lines were obtained from either American Type Culture Collection (ATCC) or Dr Stuart Aaronson (Mt Sinai, New York, NY, USA) and maintained in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10% (v/v) fetal calf serum (FCS). DI TNC1 was obtained from ATCC and propagated in DMEM supplemented with 10% FCS. NIH 3T3 was maintained in DMEM supplemented with 10% (v/v) calf serum (CS). The procedures for generating stable lines by retroviral-mediated gene transfer have been described previously (Osada et al., 1999) . Primary cultures of mouse astrocytes were prepared from postnatal day 4 pups as previously described (Banker and Goslin, 1998) . Primary human astrocytes were purchased from Cambrex Corp. (East Rutherford, NJ, USA). All tumor specimens were obtained from the University of Toronto Nervous System Tumor Bank at The Toronto Hospital. Resected tumors were placed in cryovials and immediately flash-frozen in liquid nitrogen in the operating room. A random cohort of 13 GBM specimens was processed for protein extraction in a buffer containing 50 mM HEPES, pH 7.0, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1mM EGTA, 100 mM NaF, 10 mM NaPPi, 1 mM PMSF, 2 mM leupeptin, and 2 mM aprotinin.
Expression plasmids
The pBabepuro expression constructs were generated by inserting the full-length and truncated (aa 184-283) human KLF6 cDNA (KLF6-DN) in the BamHI site of the pBabepuro vector. The pCIneo-KLF6 expression construct was created by fusing a full-length KLF6 cDNA in the EcoRI and XbaI sites of the pCIneo vector. The c-sis/PDGF-B expression plasmid has previously been described (LaRochelle et al., 1990) . The pBabepuro-v-src (Osada et al., 1999) , pCEV29-H-Ras R12 (Chan et al., 1994) , and pLTR2-EGFR (Di Fiore et al., 1987) plasmids have been described previously.
Antibodies
The polyclonal anti-KLF6 (R-173), anti-actin, and anti-p21 antibodies were obtained from Santa Cruz, Santa Cruz, CA, USA. The anti-p85 polyclonal antibody was purchased from Upstate Biotech, Lake Placid, NY, USA. The anti-GFAP monoclonal antibody was a gift from Dr David Colman (Mt Sinai, New York, NY, USA). The anti-FLAG M2 monoclonal antibody was purchased from Sigma, St Louis, MO, USA.
Western blot analysis
Unless otherwise indicated all cell solubilization steps were performed using the standard RIPA buffer. For standard Western blot analysis, 50-100 mg of total cell extracts were resolved on a 12.5% SDS-PAGE and following transfer onto nitrocellulose membranes, proteins of interest were detected by incubating with primary antibodies (a-KLF6, 1 : 400; a-actin, 1 : 2000; a-p21, 1 : 500; a-p85, 1 : 1000; a-GFAP, 1 : 1000, and aFlag, 1 : 1000) and processed by the standard ECL detection method under conditions recommended by the manufacturer (Amersham, Piscataway, NJ, USA). Filters were then subjected to autoradiography.
Cell proliferation assays
For analysis of proliferation in semisolid medium, B1 Â 10 4 cells were suspended in 0.5% agarose (Noble agar, Difco, Becton-Dickinson, Franklin Lakes, NJ, USA) in 10% CS in triplicate as described elsewhere (Chan et al., 1994) . Colonies were stained with p-iodonitrotetrazolium violet (Sigma, St Louis, MO, USA) and scored after 2 weeks. Proliferation of stably transfected cells were determined over a 5-6 day period by counting the number of cells by a hematocytometer at regular intervals.
p21 transactivation assays
DBTRG-05MG cells were plated at B80% confluence in sixwell plates and transfected using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with 1 mg of the p21 promoter reporter construct (Narla et al., 2001 ) and 2 mg of either KLF6, KLF6-DN, or a control vector. Approximately 48 h after transfection, cells were solubilized in the supplied lysis buffer and luciferase assays were performed according to the manufacturer's instructions (Promega, Madison, WI, USA).
NIH 3T3 focus forming assay
Approximately 1.5 Â 10 5. NIH3T3 cells were plated in triplicate onto a 100-mm culture dish and DNA transfection was performed by the standard calcium phosphate precipitation method (Chan et al., 1994) . Transformed foci were induced by using c-sis/PDGF-B (65 ng), v-src (30 ng), H-Ras R12 (50 ng), or EGFR (1 mg). Each oncogene plasmid was cotransfected with 2 mg of either pBabpuro, pBabpuro-KLF6, or pBabpuro-KLF6-DN. After transfection, medium was changed twice a week with 5% CS in DMEM, and the number and quality of foci were scored every week for up to 3 weeks. All plates were then fixed in 70% cold methanol and stained with Giemsa solution for detailed quantitative analysis.
In vivo tumorigenicity assays Around 2.5 Â 10 6 marker-selected cells were injected subcutaneously into both flanks of nude mice. Tumor growth was monitored every 7 days at the sites of injection. A caliper was used to determine the length, width, and height of each tumor. The volume was calculated by multiplying the length, width, and height. After approximately 5-7 weeks, each tumor was dissected and weighed. Tumor growth was presented as the total tumor volume for each animal in mm 3 .
Statistical analysis
Statistical significance was determined by Student's t test. Results are expressed as means7s.e. Statistical significance was considered to be Po0.05.
